Biosupply Trends Marketplace News
Monday, October 21, 2019
biosupply button green pixel top of biosupply button
Biosupply, place your product order MyFluVaccine, place your vaccine order Verified Inventory Program, sign up for streamlined inventory

Skin Patch Shows Promise for Delivery of Influenza Vaccine

Main article image
 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

Researchers at the University of Rochester Medical Center in New York City have developed a new type of skin patch that could replace needles as a method to deliver the influenza (flu) vaccine. While previous flu vaccine skin patches used microneedles and electroporation, which are difficult to implement on a large scale for mass vaccination, this new patch uses a protein to make the skin barrier that normally prevents toxins and allergens from entering the body more permeable. read more ]

Influenza Vaccine May Reduce Risk of Heart Attack and Stroke in Hypertensive Individuals

A new study shows an association between influenza (flu) vaccination during the flu season and an 18 percent reduction in relative risk of dying from all causes, a 16 percent less relative risk of dying from a cardiovascular event and a 10 percent lower relative risk of dying from a heart attack or stroke. read more ]

Study Finds Safe Treatment for Children with Severe Hemophilia A with Inhibitors

Researchers have found combining immune tolerance induction (in which factor VIII is given regularly over a period of time until the body is trained to recognize the product without reacting against it) with Hemlibra (emicizumab, Roche) is a feasible and safe way of treating children with severe hemophilia A. Hemlibra is a nonfactor replacement therapy to treat hemophilia A patients with or without inhibitors.
read more ]

Why the Pharma Industry Depends on In-Stock and Cold-Chain Compliant Biopharma Products

FFF Enterprises wrote an article that was featured in the September issue of Pharmaceutical Commerce magazine. With cold-chain biopharma products totaling more than $360 billion worldwide in 2019, it is essential for the pharma industry to utilize SMART refrigeration technology. In 2018, the pharma industry spent $15 billion on cold chain logistics. And, a national survey suggested up to 5% of vaccines are wasted, potentially costing up to $31 million due to cold chain lapses, followed by expiration. read more ]

Industry News

 
Industry News Image
 

From Octapharma USA

Octapharma USA is introducing two new von Willebrand Disease (VWD) clinical trials focused on prophylactic treatment and pregnancy. read more ]

From GlaxoSmithKline

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) for use in children as young as 6 years old living with severe eosinophilic asthma. It is the only targeted biologic approved for the condition in the 6- to 11-year-old age group in the U.S.  [ read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Days On Hand
     
 
 
 
     

What's New at FFF

Ambrisentan  (Par Pharmaceutical)

Ambrisentan film-coated tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). It is supplied in 5 mg and 10 mg tablet strengths and is available in the following package configurations: 5 mg 10 count bottle, 5 mg 30 count bottle, 10 mg 10 count bottle and 10 mg 30 count bottle.

For more information about Ambrisentan, log in to biosupply.fffenterprises.com

Bosentan  (Par Pharmaceutical)

Bosentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%). It is available as a 62.5 mg tablet in a bottle containing 60 tablets and a 125 mg tablet in a bottle containing 60 tablets.

For more information about Bosentan, log in to biosupply.fffenterprises.com

Treprostinil  (Par Pharmaceutical)

Treprostinil injection is a prostacyclin vasodilator indicated for pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension in patients requiring transition from epoprostenol. It is supplied in 20 mL multidose vials as sterile solutions in water for injection, individually packaged in cartons, and is available in 1 mg/mL, 2.5 mg/mL, 5 mg/mL and 10 mg/mL concentrations.

For more information about Treprostinil, log in to biosupply.fffenterprises.com

KOATE  (Kedrion)

KOATE is indicated for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of clotting factor VIII. Koate provides a means of temporarily replacing the missing clotting factor to control or prevent bleeding episodes, or to perform emergency and elective surgery on individuals with hemophilia. It is supplied in a kit containing one single-use vial of Koate lyophilized powder, one vial of sterile water for injection, USP, one sterile double-ended transfer needle, one sterile filter needle, and one sterile administration set.

For more information about KOATE, log in to biosupply.fffenterprises.com

ELCYS  (EXELA PHARMA SCIENCES)

ELCYS (cysteine hydrochloride injection) is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN) and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. Each 10 mL of ELCYS contains 500 mg of cysteine hydrochloride, USP (equivalent to 345 mg of cysteine) in water for injection. Sodium hydroxide and/or hydrochloric acid are used as needed to adjust the pH range from 1.0 to 2.5.

For more information about ELCYS, log in to biosupply.fffenterprises.com

CEFTAZIDIME USP AND DEXTROSE USP  (B. BRAUN MEDICAL INC.)

CEFTAZIDIME for injection USP and DEXTROSE injection USP are cephalosporin antibacterials indicated for treatment of the following infections caused by susceptible isolates of the designated microorganisms: lower respiratory tract infections, skin and skin-structure infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections and central nervous system infections. They are supplied in 1 gram in 50 mL and 2 grams in 50 mL DUPLEX containers.

For more information about CEFTAZIMIDE and DEXTROSE, log in to biosupply.fffenterprises.com

CEFTRIAXONE AND DEXTROSE  (B. BRAUN MEDICAL INC.)

Ceftriaxone for injection and Dextrose injection are cephalosporin antibacterials indicated for treatment of the following infections caused by susceptible isolates of the designated bacteria: lower respiratory tract infections, skin and skin structure infections, complicated and uncomplicated urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis and surgical prophylaxis. They should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Both are supplied in dual chamber, single-use containers consisting of 1 gram ceftriaxone for injection and 50 mL of 3.74% dextrose injection; and 2 grams ceftriaxone for injection and 50 mL of 2.22% dextrose injection.

For more information about CEFTRIAXONE and DEXTROSE, log in to biosupply.fffenterprises.com

CEFOTETAN AND DEXTROSE  (B. BRAUN MEDICAL INC.)

CEFOTETAN for injection USP and DEXTROSE injection USP is indicated for therapeutic treatment of the following infections when caused by susceptible strains of the designated organisms (see prescribing information): 1) urinary tract infections, 2) lower respiratory tract infections, 3) skin and skin structure infections, 4) gynecologic infections, 5) intra-abdominal infections and 6) bone and joint infections. They are supplied as a sterile, nonpyrogenic, single use packaged combination of Cefotetan disodium and Dextrose injection (diluent) in the DUPLEX sterile container.

For more information about CEFOTETAN AND DEXTROSE, log in to biosupply.fffenterprises.com

MEROPENEM AND SODIUM CHLORIDE  (B. BRAUN MEDICAL INC.)

MEROPENEM for injection USP and SODIUM CHLORIDE injection USP is a penem antibacterial indicated as single agent therapy for the treatment of complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only); complicated intra-abdominal infections (adult patients and pediatric patients 3 months of age and older requiring the full adult dose only); and bacterial meningitis (pediatric patients 3 months of age and older requiring the full adult dose only). They are supplied as 500 mg Meropenem for injection USP and 50 mL sodium chloride injection 0.9% USP, and 1 gram Meropenem for injection USP and 50 mL sodium chloride injection 0.9% USP in DUPLEX containers.

For more information about MEROPENEM AND SODIUM CHLORIDE, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective Oct. 1, 2019, through Dec. 31, 2019.

 
Calculate your current medicare IVIG/SCIG Rates
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Flebogamma J1572 $71.17 $70.03
Gammagard S/D J1566 $122.41 $120.44
Gammaplex J1557 $91.65 $90.18
Octagam J1568 $71.37 $70.22
Privigen J1459 $80.24 $78.96
SCIG
CUVITRU J1555 $137.87 $135.66
Hizentra J1559 $104.37 $102.70
HyQvia J1575 $145.56 $143.23
IVIG / SCIG
Gammagard Liquid J1569 $74.94 $73.73
Gammaked J1561 $78.28 $77.02
Gamunex-C J1561 $78.28 $77.02

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 
Log in to BioSupply for Immune Globulin Products

Resources

FFF customers may order the following complementary resources to help you with your practice:

Seasonal Flu Poster flu myths and facts brochure
immune globulin reference charts
•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to IG Living
IG Living Magazine cover
BioSupplyTrends Quarterly Magazine cover

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Subscribe to Biosupply Trends Quarterly Magazine
small Biosupply logo small MyFluVaccine logo Verified Inventory Program logo
Home | About | Advertise | Subscribe | Contact – ©FFF Enterprises, Inc.